Market Cap 342.14M
Revenue (ttm) 880,000.00
Net Income (ttm) -103.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,718.18%
Debt to Equity Ratio 0.00
Volume 1,690,000
Avg Vol 1,562,672
Day's Range N/A - N/A
Shares Out 114.05M
Stochastic %K 47%
Beta 1.71
Analysts Strong Sell
Price Target $12.79

Company Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a b...

Industry: Medical Devices
Sector: Healthcare
Phone: 206 676 0900
Address:
2401 Elliott Avenue, Suite 320, Seattle, United States
Miura1957
Miura1957 Jun. 24 at 8:38 PM
0 · Reply
morty104
morty104 Jun. 24 at 6:30 PM
$CATX anemic.
0 · Reply
jto2
jto2 Jun. 24 at 5:37 PM
$CATX Buyer pool may be broader than many assume. Lilly and Novartis come to mind. Following last week's loss in the Lutathera patent case against Curium, the urgency for Novartis to secure a next-generation alpha TAT platform may have increased, making acquisitions more of a necessity and potentially accelerating timelines. At the Goldman Sachs conference, CEO Spoor stated that the company is moving forward with a pivotal study designed around a 5 mCi dose and expects two commercial manufacturing sites to be ready by the beginning of next year. Timing could be sooner than the market currently expects.
1 · Reply
MarbleSlapper
MarbleSlapper Jun. 24 at 2:55 PM
$CATX Why short interest is high shenanigans. Anyone has a clue?
0 · Reply
JDinvestments
JDinvestments Jun. 24 at 2:52 PM
$CATX added 🥂🥂🥂 sub $3 no brainer 👍 STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀👋👋👋🤡🤡🤡
0 · Reply
Sandmansleeper
Sandmansleeper Jun. 24 at 2:51 PM
$CATX Meanwhile back at the ranch. We are $.29 cents, lower than Isoray price. As executives get fat on their salaries.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jun. 24 at 1:07 PM
$CATX 💯
0 · Reply
jive_turkey
jive_turkey Jun. 23 at 11:18 PM
$CATX we're due for a linked in job opening for an over paid quality control position that doesn't exist because we don't have a product to quality control.
0 · Reply
morty104
morty104 Jun. 23 at 5:34 PM
$CATX watch a dik ain’t so yappy these days. Baggie remorse?
0 · Reply
Miura1957
Miura1957 Jun. 23 at 4:04 PM
$CATX $0.70 just to get half of our shareholders back to even…don’t wait too long.
0 · Reply
Latest News on CATX
Perspective Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Perspective Therapeutics Earnings release: Q1 2026


Perspective Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Perspective Therapeutics Quarterly report: Q1 2026


Perspective Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Perspective Therapeutics Proxy statement: Proxy filing


Perspective Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Perspective Therapeutics Proxy statement: Proxy filing


Perspective Therapeutics Annual report: Q4 2025

Mar 16, 2026, 4:00 PM EDT - 3 months ago

Perspective Therapeutics Annual report: Q4 2025


Perspective Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 4:00 PM EDT - 3 months ago

Perspective Therapeutics Earnings release: Q4 2025


Perspective Therapeutics assumed with a Buy at Truist

2025-11-24T14:00:51.000Z - 7 months ago

Perspective Therapeutics assumed with a Buy at Truist


Perspective Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 8 months ago

Perspective Therapeutics Quarterly report: Q3 2025


Perspective Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 8 months ago

Perspective Therapeutics Earnings release: Q3 2025


Perspective Therapeutics Transcript: Study Update

Oct 20, 2025, 8:30 AM EDT - 8 months ago

Perspective Therapeutics Transcript: Study Update


Perspective Therapeutics Press release: Study Update

Oct 20, 2025, 8:30 AM EDT - 8 months ago

Perspective Therapeutics Press release: Study Update


Perspective Therapeutics Slides: Study Update

Oct 20, 2025, 8:30 AM EDT - 8 months ago

Perspective Therapeutics Slides: Study Update


Perspective Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 11 months ago

Perspective Therapeutics Quarterly report: Q2 2025


Perspective Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 11 months ago

Perspective Therapeutics Earnings release: Q2 2025


Perspective Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Quarterly report: Q1 2025


Perspective Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q1 2025


Perspective Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Proxy statement: Proxy Filing


Perspective Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Proxy statement: Proxy Filing


Perspective Therapeutics Annual report: Q4 2024

Mar 26, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Annual report: Q4 2024


Perspective Therapeutics Earnings release: Q4 2024

Mar 26, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q4 2024


Perspective Therapeutics Transcript: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Status Update


Perspective Therapeutics Press release: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Press release: Status Update


Perspective Therapeutics Slides: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Slides: Status Update


Perspective Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Perspective Therapeutics Quarterly report: Q3 2024


Perspective Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Perspective Therapeutics Earnings release: Q3 2024


Miura1957
Miura1957 Jun. 24 at 8:38 PM
0 · Reply
morty104
morty104 Jun. 24 at 6:30 PM
$CATX anemic.
0 · Reply
jto2
jto2 Jun. 24 at 5:37 PM
$CATX Buyer pool may be broader than many assume. Lilly and Novartis come to mind. Following last week's loss in the Lutathera patent case against Curium, the urgency for Novartis to secure a next-generation alpha TAT platform may have increased, making acquisitions more of a necessity and potentially accelerating timelines. At the Goldman Sachs conference, CEO Spoor stated that the company is moving forward with a pivotal study designed around a 5 mCi dose and expects two commercial manufacturing sites to be ready by the beginning of next year. Timing could be sooner than the market currently expects.
1 · Reply
MarbleSlapper
MarbleSlapper Jun. 24 at 2:55 PM
$CATX Why short interest is high shenanigans. Anyone has a clue?
0 · Reply
JDinvestments
JDinvestments Jun. 24 at 2:52 PM
$CATX added 🥂🥂🥂 sub $3 no brainer 👍 STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀👋👋👋🤡🤡🤡
0 · Reply
Sandmansleeper
Sandmansleeper Jun. 24 at 2:51 PM
$CATX Meanwhile back at the ranch. We are $.29 cents, lower than Isoray price. As executives get fat on their salaries.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jun. 24 at 1:07 PM
$CATX 💯
0 · Reply
jive_turkey
jive_turkey Jun. 23 at 11:18 PM
$CATX we're due for a linked in job opening for an over paid quality control position that doesn't exist because we don't have a product to quality control.
0 · Reply
morty104
morty104 Jun. 23 at 5:34 PM
$CATX watch a dik ain’t so yappy these days. Baggie remorse?
0 · Reply
Miura1957
Miura1957 Jun. 23 at 4:04 PM
$CATX $0.70 just to get half of our shareholders back to even…don’t wait too long.
0 · Reply
watchaddict
watchaddict Jun. 23 at 2:40 PM
$CATX 1000 lfg
0 · Reply
TheLearnerEarner
TheLearnerEarner Jun. 23 at 1:55 PM
$CATX ✅ Healthcare - Small Cap - Momentum Trap Price To Book: 1.02 (solid value) F-Score: 4/9 🏦 Analysts: 3x buy rating 👨‍🔬 (last 3 months) Highest Analysts Price Target: $18.00 (480% above Price) 🌟 (last 3 months) Range (12m) $1.96 - $6.16 💰 RSI: 38.49 (oversold bullish) 📊 NEWSDESK (article idea is for CATX only) 📰 https://uk.finance.yahoo.com/news/perspective-therapeutics-expands-therapeutic-focus-103000878.html
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jun. 23 at 11:42 AM
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jun. 22 at 10:10 PM
$CADL $IOVA $CATX https://www.aha.org/news/headline/2026-06-22-fda-announces-actions-accelerate-drug-development
0 · Reply
rughead64
rughead64 Jun. 22 at 7:41 PM
$CATX will the last 5 minutes and early AH be like Thursday?
1 · Reply
bhunts4
bhunts4 Jun. 22 at 3:03 PM
$CATX Happy Monday to all.
0 · Reply
morty104
morty104 Jun. 22 at 12:56 PM
$CATX time to play the .29999998 game.
0 · Reply
morty104
morty104 Jun. 19 at 2:27 PM
$CATX the only way it doesn’t turn red is on national holidays
0 · Reply
markbass2341
markbass2341 Jun. 18 at 10:13 PM
$CATX Volume 7.66million
0 · Reply
rughead64
rughead64 Jun. 18 at 9:06 PM
$CATX markets closed friday so we need to wait until monday to see if volume continues. Iver 7 5 million today
0 · Reply
Jcljack26
Jcljack26 Jun. 18 at 8:08 PM
$CATX is a BP accumulating for a takeover attempt?
2 · Reply
jive_turkey
jive_turkey Jun. 18 at 8:06 PM
$CATX 7.7m shares, what is going on here? rule of thumb with this POS is it's probably not good for us.
1 · Reply